; The Radiation Research and Translational Biology, (RRTB) program goal is to improve combination radiation therapies by 1) designing and testing new molecular targets identified by mechanistic studies, and 2) addressing tumor resistance to therapy and bypass of immune surveillance, and 3) designing, assessing and improving technologies that diagnose, stage, and deliver therapies for cancer patients. Program members address these goals with multidisciplinary efforts in biochemistry, immunology, drug design, preclinical models, and clinical experience, to accelerate translation from bench to bedside. The Program has been strengthened by integration of members from the former Program in Cancer Immunology. The current RRTB program, comprised of 34 basic, translational and clinical investigators from eleven departments, thus combines basic and clinical research strengths to conduct bench to bedside research and can reverse translate clinical data to inform further translational innovations. This work is supported by 36 peer-reviewed grants totaling direct funds of $13.2 million ($5.3 million from NCI). The total number of publications generated by Program members from 2007 to 2012 is 543 of which 11% are Intra-programmmatic and 22% are Inter-programmatic, with 4.6% being both. The specific research themes ofthe RRTB Program are: (1) Improve RT therapies by defining and characterizing molecular targets for ionizing radiation and for combined therapies, vaccine development and BMT (2) Immune tolerance and strategies for immune surveillance. (3) Tumor resistance: Microenvironment, hypoxia and angiogenesis. (4) Protecting normal tissues: normal tissue injury/genotoxic stress. (5) Clinical translation of diagnostic and therapeutic innovations, and (6) Improving clinical practice: Biomedical/Bioinformatics and Comparitive Effectiveness Research (CER). This program will continually generate new collaborations, intra- and interprogrammatically, and fresh research directions with other research programs in the cancer center.
; The Radiation Research and Translational Biology (RRTB) program is improving cancer treatment by increasing the killing of cancer cells while protecting normal tissues. Its basic and clinical researchers combine innovations in radiation technology and imaging techniques with drugs targeting tumor cells (or the surrounding tissues) to help physicians make better diagnoses and choose the best course of therapy.
|Liao, Lili; Liu, Zongzhi Z; Langbein, Lauren et al. (2018) Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer. Elife 7:|
|Heeke, Arielle L; Pishvaian, Michael J; Lynce, Filipa et al. (2018) Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types. JCO Precis Oncol 2018:|
|Parent, Kristin N; Schrad, Jason R; Cingolani, Gino (2018) Breaking Symmetry in Viral Icosahedral Capsids as Seen through the Lenses of X-ray Crystallography and Cryo-Electron Microscopy. Viruses 10:|
|Rappaport, Jeffrey A; Waldman, Scott A (2018) The Guanylate Cyclase C-cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia. Front Oncol 8:299|
|Pandya, Kalgi D; Palomo-Caturla, Isabel; Walker, Justin A et al. (2018) An Unmutated IgM Response to the Vi Polysaccharide of Salmonella Typhi Contributes to Protective Immunity in a Murine Model of Typhoid. J Immunol 200:4078-4084|
|Hussain, Maha; Daignault-Newton, Stephanie; Twardowski, Przemyslaw W et al. (2018) Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol 36:991-999|
|Shafi, Ayesha A; Schiewer, Matthew J; de Leeuw, Renée et al. (2018) Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. Eur Urol Oncol 1:325-337|
|Meyer, Sara E; Muench, David E; Rogers, Andrew M et al. (2018) miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. J Exp Med 215:2115-2136|
|Mazina, Olga M; Mazin, Alexander V (2018) Reconstituting the 4-Strand DNA Strand Exchange. Methods Enzymol 600:285-305|
|Magee, Michael S; Abraham, Tara S; Baybutt, Trevor R et al. (2018) Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. Cancer Immunol Res 6:509-516|
Showing the most recent 10 out of 807 publications